Big Pharma’s synthetic cannabis pills are killing people

New Post Public Reply Private Reply Replies (6) Message Board
wowhappens28 john1234 #17058
321
Big Pharma’s synthetic cannabis pills are killing people … yet authentic marijuana is still criminalized.

"Big Pharma" and "Big Government" are one, exist to help "The Borg" "Resistance was futile" until Trump arrived. I am not 100% convinced yet about Trump, but he is sure off to a fantastic start in destroying "The Borg"

http://www.naturalnews.com/2017-01-27-big-pha...lized.html

(Natural News) Leave it to Big Pharma to find a way to turn a natural, effective, plant-based healing substance into something patentable and deadly.

That’s right; the guys in the pharmaceutical labs are so desperate to develop a drug that delivers the same therapeutic benefits as cannabis – under their own exclusive money-making patent, of course – that they don’t mind if a few people die along the way.

That’s what happened last year in France, when a clinical trial involving a synthesized laboratory drug designed to stimulate the body’s endocannabinoid receptor system left six people hospitalized, one of whom was later declared brain-dead.

The pharmaceutical industry has long been in the business of isolating or synthesizing the active ingredients of medicinal plants and patenting the resulting drugs so that huge profits can be made, and they often look to governments to aid them in obtaining exclusive rights and eliminating competition.

From True Activist:

“[W]hen government-connected industries wish to shut out their competition, which in this case is a plant, they lean on the state’s ability to stifle competition through claiming a right to the intellectual property behind a particular set of ingredients – otherwise known as a patent.

“Since no one can patent a wild plant, pharmaceutical industries turn to their labs and chemistry to recreate nature.”

But to reproduce the wide-ranging and nearly-miraculous therapeutic properties of cannabis in a laboratory is no simple task. The effects of cannabis on the human body are very complex, and there are many active compounds contained within the plant.

Scientists have only recently discovered what is called the endogenous cannabinoid system (ECS), and it’s the key to how and why cannabis works so well to alleviate pain and even cure many illnesses.

From Reset.me:

“Cannabis medications work so efficiently because of the endocannabinoid (EC) system, present in all humans and many animals as well. This system consists of a series of receptors that are configured only to accept cannabinoids, especially tetrahydrocannabinol (THC) and cannabidiol (CBD).” (RELATED: See more news about cannabidiol at CBDs.news)

The way this system works is just beginning to be understood, and the death and hospitalizations that occurred as one drug company rushed to test its own lab-based synthetic ECS stimulant is a testament to the fact that we simply don’t understand the endogenous cannabinoid system well enough yet to begin subjecting humans to experimental drugs designed to affect it.

What we do know, however, is that the “whole” cannabis plant delivers all of the therapeutic benefits, without any dangerous side effects.

That fact scares the hell out of the pharmaceutical industry, because they are seeing people discarding pain pills and other drugs in favor of a natural remedy that costs nothing to grow.

That’s also why Big Pharma is continuing to put pressure on the government to keep marijuana classified as a dangerous drug and to stifle research into the use of the natural plant as opposed to dangerous, government-approved chemical drug research and development.

Fortunately, the prohibition of marijuana is failing. As more and more studies confirm the therapeutic benefits of the plant itself, and the old attitudes and stigma regarding marijuana begin to fade into the past, it will be difficult to continue convincing the public that the plant should be outlawed and that only government-approved chemical cannabis substitutes should be made available.

But the battle isn’t over yet. We, as citizens, must continue to demand the right to have access to cannabis and to be able to grow it at home. Until the federal government completely legalizes marijuana and removes it from the list of controlled substances, the fight isn’t over.

Big Pharma’s chemical version of cannabis is not an acceptable substitute for the real thing.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Amgen's Board Gains Restaurateur Gibbs Amid Strategic Shift

Updated Category News Views 86

A Heavyweight Joiner Shakes Up Amgen's Ranks You can almost feel the ground shake when Amgen, a tech giant in biotech, ropes in a high-profile namesake from outside its usual league. David W. Gibbs, the former CEO of Yum! Brands, is now staking his claim at Amgen as a member of its Board of Directors. Effective immediately, Gibbs isn’t just a filler; he's diving...

Continue Reading
AI's Rise: Worth Watching for M&A Strategy Insights

Updated Category News Views 0

AI: The Hot Topic You Can't Ignore AI's rocking the boat like SEO did back in the day, folks. The Digital WOW is giving M&A Source® members a real scoop with their exclusive webinar, zeroing in on AI's potential seismic shifts in mergers and acquisitions. This should make any investor sit up and pay attention. AI's not just a tech buzzword anymore. It's like a strong cup...

Continue Reading
Cumberland Pharmaceuticals Eyes NDA for Ifetroban in DMD

Updated Category News Views 72

Rolling the Dice with Ifetroban There's a buzz in the air around Cumberland Pharmaceuticals as they gear up to tackle one of medicine's stubborn giants, Duchenne muscular dystrophy (DMD). They plan to file a New Drug Application (NDA) with the FDA for ifetroban, aiming to treat the cardiomyopathy plaguing many DMD sufferers. Folks who’ve watched Cumberland (NASDAQ:CPIX)...

Continue Reading
Texas Instruments' $2B Notes Fuel Acquisition Ambitions

Updated Category News Views 128

Pushing Forward with Big Dollars Texas Instruments is setting the stage with an ambitious move by pricing $2.0 billion in investment-grade notes, preparing to shake things up with an acquisition. It's not every day you see a player like TXN dipping into the bond market with such confidence, yet here we are. Four series of senior unsecured notes are slated for issuance on...

Continue Reading
E-Filing: Why Ditching IRS Paper Forms Matters Now

Updated Category News Views 153

Tax Filing Today: The Old vs. The New Listen up, tax-filing warriors. Tackling that IRS Form 941 deadline isn’t just another play in the small business game—it’s crunch time. November 2, 2026, isn’t waiting around for excuses. Luckily, Halfpricesoft.com just chucked you a lifeline with their updated ezPaycheck platform. Swap that mountain of mangled paper forms...

Continue Reading
Custom Concrete: Crafting the Perfect Poolside Paradise

Updated Category News Views 48

Concrete: The Unsung Hero of Your Pool's Success You know, everyone always raves about that sparkling pool, but let's be real—it's the concrete holding the whole gig together. James White from White's Pools in Loganville, GA, drops some knowledge in a recent HelloNation piece about the unsung hero of backyard oases: custom concrete. Yeah, it's not sexy, but when you're...

Continue Reading
Bertram Capital Backs MCE's Expansive Growth Vision

Updated Category News Views 116

A Strategic Move for Bertram Capital Right on the heels of seasoned market moves, Bertram Capital has thrown its support behind Motion & Control Enterprises (MCE). This isn't just another portfolio addition; it's a calculated step into the complex world of industrial distribution, partnering with a company renowned for its prowess in engineered solutions. If you've ever...

Continue Reading
Energy Fuels Secures Key Financing for Donald Project

Updated Category News Views 53

Donald Project: A Step Closer to Reality Look, when those rare earths start moving, the entire market gets a whiff of promise. Energy Fuels' Donald Rare Earth and Mineral Sands Project in Australia is gearing up for real action with a fresh funding nod. Export Finance Australia and the National Reconstruction Fund Corporation have conditionally greenlit up to A$180...

Continue Reading
Skechers Facing Class Action: Investors Urged to Act

Updated Category News Views 93

Skechers Under Fire: Fraud Allegations Surface Alright, if you've been around the stock block a while, you know these stories can often read like a suspense novel. Plot twist: Skechers U.S.A., Inc. (formerly NYSE: SKX) is now facing some serious accusations. There's a class action lawsuit claiming that some shady dealings went down during the company's $9.4 billion...

Continue Reading
Brennan Takes a Swing: Barrasso Endorsement in Hand

Updated Category News Views 60

Brennan Shakes Up Wyoming Politics You don’t need a crystal ball to see the chess game unfolding in Wyoming's political landscape. Shannon Brennan's bid for the House seat in Teton County's District 23 got a heavy artillery boost today. She’s landed the endorsement of Senator John Barrasso, none other than the Senate Majority Whip and a formidable player in the Senate...

Continue Reading

Top 5 Most Recently Viewed Articles

Rehabilitation Robots Market Growth and Future Opportunities

Updated Category News Views 187

The Future of Rehabilitation Robots As the healthcare landscape evolves, the rehabilitation robots market is witnessing remarkable growth, projected to reach approximately USD 1,776.24 million in the forthcoming years. This burgeoning sector aims to enhance the recovery processes for individuals across various age groups, especially the elderly, who often require...

Continue Reading
Kean University Strengthens Leadership with New Contract for Repollet

Updated Category News Views 152

Kean University’s New Chapter: A Strong Commitment to Leadership The Kean University Board of Trustees recently reached a pivotal decision about the university's future by approving a new five-year contract for President Lamont O. Repollet, Ed.D. This decision highlights the institution's dedication to transformative leadership as it works to enhance its reputation as a...

Continue Reading
Kura Sushi USA Prices Public Offering to Boost Growth Efforts

Updated Category News Views 327

Kura Sushi USA Public Offering Announcement Kura Sushi USA, Inc. (NASDAQ: KRUS), a pioneer in the technology-enabled Japanese dining experience, has recently priced a public offering of its Class A common stock. This strategic move is not just about fundraising; it reflects the Company's ambition to bolster its operational capacity and expand its reach. The offering...

Continue Reading
Grady Health System Receives Gold Plus Award for Excellence

Updated Category News Views 192

Grady Health System's Recognized Commitment to Stroke Care Grady Health System, home to the renowned Marcus Stroke and Neuroscience Center, has achieved the prestigious Gold Plus quality achievement award from the American Heart Association's Get With The Guidelines - Stroke program. This accolade highlights Grady's unwavering dedication to delivering exceptional stroke...

Continue Reading
Investors Urged to Act as Visa Faces Legal Challenges

Updated Category News Views 108

Investors Encouraged to Step Forward Amid Legal Investigation Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson is reaching out to investors who have suffered losses exceeding $100,000 in Visa to discuss their legal options directly. If you have experienced losses greater than $100,000 in Visa, it's essential to take action. You can connect with...

Continue Reading